Know Cancer

or
forgot password

A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)


Phase 1/Phase 2
18 Years
N/A
Open (Enrolling)
Both
B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma

Thank you

Trial Information

A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)


PRIMARY OBJECTIVES:

I. To estimate the maximum tolerated dose (MTD) of vorinostat that can be combined with
fludarabine (fludarabine phosphate), cyclophosphamide and rituximab (FCR) in patients with
previously untreated CLL/SLL.

II. To evaluate potential efficacy in terms of 2-year after FCR plus vorinostat induction
followed by rituximab plus vorinostat maintenance therapy for previously untreated CLL/SLL
patients.

SECONDARY OBJECTIVES:

I. To eliminate residual disease (documented by flow cytometry and/or polymerase chain
reaction [PCR]) in patients who have achieved a CR after FCR plus vorinostat.

II. To estimate the rate of conversion of partial response (PR) to complete response (CR)
after FCR plus vorinostat.

OUTLINE: This is a phase I, dose-escalation study of vorinostat followed by a phase II
study.

INDUCTION THERAPY: Patients receive vorinostat orally (PO) once daily on days 1-5 and 8-12;
cyclophosphamide intravenously (IV) over 30-60 minutes and fludarabine IV over 30-60 minutes
on days 1-3; and rituximab IV on day 1, 2, 3, 4, or 5. Treatment repeats every 28 days for
4-6 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE THERAPY: Beginning 3 months after the completion of induction therapy, patients
receive vorinostat PO on days 1-14 and rituximab IV on day 1. Treatment repeats every 3
months for 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for 5 years and
then annually thereafter.


Inclusion Criteria:



- Patients must have a confirmed diagnosis of CLL/SLL

- Patients with previously untreated cluster of differentiation (CD)20+ CLL/SLL must
have either Rai stage III/IV disease or be Rai stage I/II with evidence of disease
activity as defined by the National Cancer Institute (NCI) 1996 guidelines; patients
with SLL must be Stage III or IV per Ann Arbor staging system

- Patient must have consented to participate in the study and signed and dated an
appropriate institutional review board (IRB)-approved consent form that conforms to
federal and institutional guidelines

- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of
0, 1 or 2

- Patient must have an anticipated (untreated) survival of at least 3 months

- Female patient of childbearing potential has a negative serum pregnancy test
beta-human chorionic gonadotropin (hCG) within 72 hours prior to receiving the first
dose of vorinostat

- Female patient is either post menopausal, free from menses for >= 2 years, surgically
sterilized or willing to use 2 adequate barrier methods of contraception to prevent
pregnancy or agrees to abstain from heterosexual activity throughout the study,
starting with Visit 1

- Male patients not sterilized must be willing to use adequate barrier methods of
contraception to prevent pregnancy or agrees to abstain from heterosexual activity
throughout the study, starting with Visit 1

- Absolute Neutrophil Count (ANC) >= 1,500/mcL

- Platelets >= 100,000/mcL

- Hemoglobin >= 9 g/dL

- Prothrombin time or international normalized ratio (INR) =< 1.5 upper limit of normal
(ULN) unless receiving therapeutic anticoagulation

- Partial thromboplastin time (PTT) =< 1.2 times the ULN unless the patient is
receiving therapeutic anticoagulation

- Potassium level within normal limits

- Magnesium level within normal limits

- Serum creatinine =< 1.5 x ULN OR if creatinine is > 1.5 ULN the calculated creatinine
clearance must be >= 60 mL/min

- Serum total bilirubin =< 1.5 times ULN; patients with Gilbert's disease or similar
syndrome involving slow conjugation of bilirubin are eligible with total bilirubin >
1.5 times upper limit of normal; primary investigator (PI) review and approval
required for anything above 2 times ULN

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =<
2.5 ULN

- Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5
ULN

- Alkaline Phosphatase =< 2.5 ULN

- Patients with cytopenias due to disease or pseudohyperkalemia that do not meet these
criteria, will be considered eligible with review and approval by the PI or Co-PI
prior to study entry

Exclusion Criteria:

- Patients who have received cytotoxic chemotherapy, radiation therapy, immunotherapy,
or cytokine treatment prior to study entry for CLL/SLL; patients who have received
systemic steroids within 1 week of study entry are excluded, except patients on
maintenance steroid therapy for a noncancerous disease

- Patients with active hemolysis

- Patients must not require sustained transfusion support of blood products

- Patients who have undergone treatment with either stem cell or bone marrow transplant

- Patients with active obstructive hydronephrosis

- Patients with evidence of any significant systemic illness, active Hepatitis B
infection, active viral hepatitis infection or other active infection at the time of
study entry

- Patients with New York Heart Association class III or IV heart disease symptomatic
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or other
serious illness, such as acute or chronic graft versus host disease, that would
preclude evaluation

- Patients with congenital long QT syndrome and patients taking antiarrhythmic
medicines or other medicinal products that lead to QT prolongation will only be
eligible if their baseline QTc prolongation is =< 500 msec

- Patients with known human immunodeficiency virus (HIV) infection

- Patients who are pregnant or nursing

- Patients with known brain or leptomeningeal involvement by malignancy

- Patients who have, in the opinion of the investigator, other medical, social, or
psychosocial factors that may negatively impact compliance or their safety by
participation in this study

- Patient is currently participating or has participated in a study with an
investigational compound or device within 30 days of initial dosing with study
drugs(s)

- Patient had prior treatment with an histone deacetylases (HDAC) inhibitor (e.g.,
romidespin (Depsipeptide), NSC-630176, MS 275, LAQ-824, belinostat (PXD-101), LBH589,
MGCD0103, CRA024781, etc); patients who have received compounds with HDAC
inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not
enroll in this study; patients who have received such compounds for other
indications, e.g. valproic acid for epilepsy, may enroll after a 30-day washout
period

- Patient with a history of a prior malignancy with the exception of cervical
intraepithelial neoplasia; non-melanoma skin cancer; adequately treated localized
prostate carcinoma with prostate-specific antigen (PSA) =< 1.0; or who has undergone
potentially curative therapy with no evidence of that disease for five years, and/or
who is deemed at low risk for recurrence by his/her treating physician

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

MTD of vorinostat that can be combined with fludarabine phosphate, cyclophosphamide and rituximab (Phase I)

Outcome Time Frame:

28 days

Safety Issue:

Yes

Principal Investigator

John Pagel

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Authority:

United States: Federal Government

Study ID:

PSOC 2401

NCT ID:

NCT00918723

Start Date:

May 2009

Completion Date:

Related Keywords:

  • B-cell Chronic Lymphocytic Leukemia
  • Contiguous Stage II Small Lymphocytic Lymphoma
  • Noncontiguous Stage II Small Lymphocytic Lymphoma
  • Stage I Chronic Lymphocytic Leukemia
  • Stage I Small Lymphocytic Lymphoma
  • Stage II Chronic Lymphocytic Leukemia
  • Stage III Chronic Lymphocytic Leukemia
  • Stage III Small Lymphocytic Lymphoma
  • Stage IV Chronic Lymphocytic Leukemia
  • Stage IV Small Lymphocytic Lymphoma
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Lymphoma

Name

Location

Puget Sound Oncology ConsortiumSeattle, Washington  98109
Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumSeattle, Washington  98109